Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).

Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ.

Haematologica. 2016 Jun;101(6):781-8. doi: 10.3324/haematol.2015.140335. Epub 2016 Mar 4.

2.

Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?

Gyurkocza B, Deeg HJ.

Blood Rev. 2012 Nov;26(6):247-54. doi: 10.1016/j.blre.2012.08.002. Epub 2012 Sep 13. Review.

3.

Hematopoietic stem cell transplantation for MDS.

Bartenstein M, Deeg HJ.

Hematol Oncol Clin North Am. 2010 Apr;24(2):407-22. doi: 10.1016/j.hoc.2010.02.003. Review.

4.

The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes.

Diamantidis M, Dimoudis S, Klonizakis P, Badekas K, Koutourli K, Haralambidou-Vranitsa S, Ioannidou-Papagiannaki E.

Hippokratia. 2007 Oct;11(4):178-82.

5.

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.

Gattermann N.

Int J Hematol. 2008 Jul;88(1):24-9. doi: 10.1007/s12185-008-0118-z. Epub 2008 Jun 27. Review.

6.

Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.

Suzuki T, Tomonaga M, Miyazaki Y, Nakao S, Ohyashiki K, Matsumura I, Kohgo Y, Niitsu Y, Kojima S, Ozawa K.

Int J Hematol. 2008 Jul;88(1):30-5. doi: 10.1007/s12185-008-0119-y. Epub 2008 Jun 27. Review.

7.

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.

Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L.

Br J Haematol. 2008 Jul;142(3):379-93. doi: 10.1111/j.1365-2141.2008.07181.x. Epub 2008 Jun 6.

8.
9.

Supplemental Content

Support Center